• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Osteoporosis : The Silent Thief 	 Osteoporosis : The Silent Thief
 

Osteoporosis : The Silent Thief Osteoporosis : The Silent Thief

on

  • 1,685 views

 

Statistics

Views

Total Views
1,685
Views on SlideShare
1,671
Embed Views
14

Actions

Likes
1
Downloads
112
Comments
0

2 Embeds 14

http://www.slideshare.net 11
http://juxnsantana.blogspot.com 3

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Osteoporosis : The Silent Thief 	 Osteoporosis : The Silent Thief Osteoporosis : The Silent Thief Osteoporosis : The Silent Thief Presentation Transcript

    • Osteoporosis : The Silent Thief
      • OSTEOPOROSIS has been defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of the bone tissue, with a consequent increase in bone fragility and susceptibility to fracture
      O STEO F OS Amount of bone resorbed >>> Amount of bone formed by osteoclasts by osteoblasts ¯ BONE LOSS
    • Osteoporotic bone remodelling O STEO F OS
    • Bone Remodelling With Alendronate O STEO F OS
    • Mode Of Action
      • Gets preferentially bound under osteoclasts. Osteoclasts ingest the attached alendronate. Released alendronate inactivates the osteoclasts. Bone resorption inhibited.
      • Alendronate may reduce the number of remodelling sites
      O STEO F OS
    • Mode Of Action (Contd.)
      • Inhibits cytokine production by osteoblasts
      • Supports the osteoblast mediated bone formation
      • Induces the osteoblasts to synthesize a substance which may directly inhibit the osteoclastic resorption
      • Alendronate inhibits the osteoclastic bone resorption
      • without inhibiting the osteoblastic bone formation –
      • increase in bone mass
      O STEO F OS
    • Design of the FIT Trial Screening Visits * BMD ( < 0.68 g/cm 2 ) * Other eligibility * Vertebral X-ray Vertebral Deformity Present Vertebral Deformity Absent Vertebral Deformity Study Randomize (N=2027) 3 years Prim. Endpoint New Vertebral Deformity Sec. Endpoint All Clinical Fractures Clinical Fracture Study Randomize (N=4434) 4.25 years Prim. Endpoint Any Clinical Fracture Sec. Vertebral Deformity O STEO F OS
    • FIT Trial - Increase in BMD at Femoral Neck 4.1% increase in BMD with Alendronate p<0.001 % of patients Lancet, 348, 1996 Months alendronate placebo O STEO F OS
    • FIT TRIAL - Summary of Fracture Results
      • Type of fracture % incidence P value reduction
      • At least one new vertebral fracture 47 <0.001
      • Multiple ( > 2) new vertebral fractures 90 <0.001
      • Clinical (symptomatic) vertebral fracture 55 <0.001
      • Hip fracture 51 0.047
      • Wrist fracture 48 0.013
      Lancet, 348, 1996 O STEO F OS
    • Alendronate plus Hormone Replacement Therapy (HRT) 428 postmenopausal women receiving HRT (average duration of treatment 9.5 years) Bone mass : > 2 SD below normal Average age : 62 years Average duration of menopause : 15 years 214 women continued on HRT for one year 214 women received alendronate 10 mg/day along with HRT for one year Inpharma 26 Sept’ 1998, No. 1156: 18
    • Alendronate plus Hormone Replacement Therapy (HRT) Bone mass HRT alone group Combination therapy group (alendronate + HRT) Percentage increases in bone mass from baseline after 1 year’s treatment Inpharma 26 Sept’ 1998, No. 1156: 18 Addition of Alendronate to Hormone Replacement Therapy (HRT) results in 2 to 5 times greater increase in Bone Mineral Density (BMD) than HRT alone
    • Steroid-induced Osteoporosis
      • Majority of bone loss occurs in the beginning (10-20%)
      • 25% may experience a fracture
      • 4 fold increase in all fractures
      • Usually affects vertebrae, ribs, hip
      • Risk higher in patients with higher dose, taking longer, low BMD etc
      Cause  Calcium  Urinary Calcium  Osteoblast absorption excretion formation and function
    • Alendronate in Steroid-Induced Osteoporosis (Patients receiving 7.5 mg Prednisone) Age : 17-83 year NEJM 1998; 339: 292-9. 4 2 0 -2 12 24 36 48 Lumbar Spine M e a n ( S E ) P e r c e n t C h a n g e i n B o n e M i n e r a l D e n s i t y + Week Placebo n=159 5 mg of alendronate n=161 10 mg of alendronate n=157
    • Early Postmenopausal Intervention Cohort Study (EPIC) NEJM 1998; 338(8): 485-492. 1609 postmenopausal women (aged 45 to 59 years) Study Centres : US and Europe Placebo n = 502 Alendronate 2.5 mg/day n = 499 Alendronate 5 mg/day n = 498 Estrogenprogestin n = 110
    • Hip Bone Mineral Density NEJM 1998; 338(8): 485-492. 0% 20% 40% 60% 80% 100% Placebo 2.5 mg of alendronate 5 mg of alendronate Estrogen- progestin >2% gain  2% change >2% loss Women (%)
    • Early Postmenopausal Intervention Cohort Study (EPIC)
      • Results of US Cohort : Percentage increase in BMD at end of 2 years
      • Alendronate HRT P
      • Hip bone 1.3 + 0.3 1.8 + 0.3 P = 0.21
      • Lumber Spine 2.9 + 0.5 4.0 + 0.3 P = 0.06
      • Total body 0.8 + 0.3 1.2 + 0.2 P = 0.29
      NEJM 1998; 338(8): 485-492.
    • Alendronate Osteoporosis Prevention Study Group Annals of Internal Medicine, 1998; 128 : 253-261 447 women < age 40 to 59 years > Duration of menopause : 6 to 36 months before study entry Duration of trial : 3 years Placebo n = 90 Alendronate 1 mg/day n = 92 Alendronate 5 mg/day n = 88 Alendronate 10 mg/day n = 88 Alendronate 20/0 mg/day n = 89
    • Alendronate Osteoporosis Prevention Study Group (Contd.) Annals of Internal Medicine, 1998; 128 : 253-261 Mean changes from baseline in Bone Mineral Density 0 -3 -3 -2 -1 0 1 2 3 4 5 6 12 18 Month Mean change in Trochanter Bone Mineral Density, Percentage Points 24 30 36 0 -3 -2 -1 0 1 2 6 12 18 Month Mean change in Total Body Bone Mineral Density, Percentage Points 24 30 36 Placebo 1 mg/d 5 mg/d 10 mg/d 20/0 mg/d
    • Alendronate in Men with Primary Osteoporosis – Interim Results (12 months) of an Ongoing Study * BMD Inpharma 1999; No. 1196: Pg 13–14 Lumbar Spine *p<0.001 * Femoral Neck *p<0.04 *
      • Dosage
      • Prevention of postmenopausal osteoporosis 5 mg/day
      • Treatment of postmenopausal osteoporosis
      • 10 mg/d
      • Administration
      • Once-a-day with a full glass of plain water (200 ml) only, on an empty stomach
      • Patient should not lie down for half an hour after administration
      • Patient should not eat food for half an hour after administration
      Dosage and Administration
    • Contraindications
      • Abnormalities of the esophagus such as stricture or achalasia
      • Inability to stand or sit upright for at least 30 minutes
      • Hypersensitivity to any of the components of this product
      • Hypocalcemia
      O STEO F OS